Techsomed Launches Ultrasound-Based Software Suite for Liver Tumor Ablation Therapy
Featuring the previously FDA-cleared BioTraceIO Vision and BioTraceIO Precision modalities, the BioTrace software suite combines real-time ultrasound guidance and advanced AI technology to help bolster outcomes with liver tumor ablation therapy.
For patients with liver tumors, the emergence of a new software suite may enhance the accuracy and efficiency of ultrasound-guided treatment.
The recently launched BioTrace software suite includes BioTraceIO Vision and BioTraceIO Precision, two modalities that were previously cleared by the Food and Drug Administration (FDA) for use in liver tumor ablation, according to Techsomed, the manufacturer of the modalities.
For interventional radiologists, BioTraceIO Vision may enhance pre-op planning of liver tumor ablation procedures and BioTraceIO Precision provides assessments for post-ablation tissue damage based on real-time ultrasound images, according to Techsomed, the developer of both software modalities. (Image courtesy of Techsomed.)
For the assessment and treatment planning of patients with liver tumors, TechsoMed said interventional radiologists may utilize the artificial intelligence (AI)-powered BioTraceIO Vision for targeted ablation therapy based on ultrasound guidance. In order to access predictive insights on post-ablation tissue damage, clinicians may employ BioTraceIO Precision to get assessments based on real-time ultrasound imaging, according to Techsomed.
“We are thrilled to bring our BioTrace software suite, including both BioTraceIO Vision and BioTraceIO Precision, for patient care in the United States. … We look forward to partnering with leading medical institutions to revolutionize the standard of care in ablation therapy, offering patients the benefits of enhanced treatment precision aimed to improve outcomes,” noted Yossi Abu, the CEO of Techsomed.
Recent Videos
Related Content
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025Article
While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Article
Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025Article
The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
